🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

LAXMI DENTAL LIMITED LAXMIDENTL NSEPHARMA

Healthcare · Medical Instruments & Supplies · India
https://www.laxmidentallimited.com
Company Profile ↓
₹199.14
-49.39% 1Y
Mkt Cap₹1,094.52 Cr
P/E37.86
P/B4.89
52W High₹393.45
52W Low₹158.25
Book Value₹44.27
EPS (TTM)₹5.26

Company Overview

Laxmi Dental Limited manufactures and sells dental products in India, the United States, the United Kingdom, and internationally. It offers custom-made crowns, bridges, clear aligners, thermoforming sheets, and aligner related products, and pediatric dental products. The company serves dental clinics, dental companies, and dentist. The company was incorporated in 2004 and is based in Mumbai, India.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 276.5% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 19.5% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 37.9, below the sector median of 41.6.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.05.

Recent Developments

  • Mar 2026 Revenue of ₹271.50 Cr (+14.8% YoY); net profit ₹28.98 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +14.8%, earnings -8.8%.
  • 5-Year Trend Long-term compounding — revenue CAGR 19.5%, profit CAGR 276.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:19.54%
1 Year:14.77%

Compounded Profit Growth

5 Years:276.46%
1 Year:-8.79%

Stock Price Performance

1 Year:-49.39%
6 Months:+9.60%
3 Months:-11.28%
1 Month:-8.89%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 17% of range
₹158.25 ₹393.45
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)45.03 · Neutral
Price Performance
1M-8.89%
3M-11.28%
6M+9.60%
1Y-49.39%
Valuation vs Sector

P/E of 37.86 is below the sector median of 41.64 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 19.5% over 5 years.
  • Profit CAGR of 276.5% over 5 years.

CONS

  • Trading 49.4% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
37.86
Industry PE
41.64
Forward P/E
16.46
PEG Ratio
-
Book Value
₹44.27
Price to Book
4.89
P/S
4.27
EV/EBITDA
27.23
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
19.54%
Profit 5Y
276.46%
Revenue (YoY)
14.77%
Earnings (YoY)
-8.79%

Profitability & Returns

ROCE
11.51%
ROE
11.91%
ROA
9.86%
Profit Margin
10.67%
Op Margin
10.14%
Gross Margin
69.73%
EPS (Latest Qtr)
₹1.83
EPS (TTM)
₹5.26

Balance Sheet & Liquidity

Debt/Equity
0.05
Quick Ratio
5.42
Current Ratio
6.13
Debt
₹13.01 Cr
Total Assets
₹293.97 Cr
Current Assets
₹188.72 Cr
Working Capital
₹157.93 Cr

Ownership

Promoter Holding
68.16%
Chg in Prom Hold
-0.01%
FII / Inst Holding
17.04%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
₹1,094.52 Cr
Total Revenue (TTM)
₹271.50 Cr
EBITDA
₹46.17 Cr
Free Cash Flow
₹-23.37 Cr
Operating Cash Flow
₹-5.00 Cr
Shares Outstanding
₹5.50 Cr
Gross Margin
69.73%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 LAXMIDENTL LAXMI DENTAL LIMITED NSEPHARMA 199.14 37.86 ₹1,094.52 Cr 0.00% 11.51% 11.91% 19.54% 276.46%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,899.00 39.73 ₹4.56 L Cr 0.82% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,100.00 94.06 ₹2.42 L Cr 0.36% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,857.00 75.99 ₹1.64 L Cr 0.77% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,650.00 64.10 ₹1.24 L Cr 0.22% 19.20% 20.48% 14.85% 33.34%
6 LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA 684.90 236.17 ₹1.19 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,120.00 22.36 ₹1.13 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,385.00 28.85 ₹1.12 L Cr 0.88% 14.86% 11.27% 7.23% 11.45%
9 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 1,840.00 111.85 ₹99,333.61 Cr 0.13% 19.53% 16.77% 3.77% 4.00%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 48.00 Cr55.00 Cr60.00 Cr57.00 Cr62.00 Cr60.42 Cr64.32 Cr70.98 Cr64.02 Cr72.18 Cr
Cost of Revenue -----12.89 Cr17.51 Cr22.74 Cr20.12 Cr21.83 Cr
Gross Profit -----47.53 Cr46.81 Cr48.24 Cr43.91 Cr50.35 Cr
Operating Expenses 44.00 Cr43.00 Cr46.00 Cr48.00 Cr52.00 Cr42.30 Cr38.48 Cr40.97 Cr41.11 Cr41.23 Cr
Operating Income 1.00 Cr9.00 Cr11.00 Cr6.00 Cr6.00 Cr5.23 Cr8.33 Cr7.27 Cr2.79 Cr9.12 Cr
EBITDA 4.00 Cr12.00 Cr14.00 Cr9.00 Cr10.00 Cr11.56 Cr13.63 Cr13.41 Cr3.26 Cr15.86 Cr
Interest Expense 1.00 Cr1.00 Cr1.00 Cr1.00 Cr2.00 Cr1.26 Cr46.00 L23.90 L32.10 L34.50 L
Pretax Income -1.00 Cr7.00 Cr16.00 Cr5.00 Cr5.00 Cr6.01 Cr9.60 Cr9.42 Cr-1.23 Cr11.13 Cr
Tax Provision 1.40 Cr1.12 Cr1.76 Cr1.15 Cr1.15 Cr2.48 Cr2.29 Cr1.86 Cr-2.16 Cr50.00 L
Net Income 2.00 Cr8.00 Cr17.00 Cr6.00 Cr5.00 Cr4.28 Cr8.39 Cr8.53 Cr1.98 Cr10.08 Cr
Diluted EPS 74.05243.916.042.120.930.771.521.580.361.83

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 150.00 Cr92.00 Cr-158.94 Cr191.45 Cr236.56 Cr271.50 Cr
Cost of Revenue ---42.66 Cr48.53 Cr57.24 Cr82.19 Cr
Gross Profit ---116.28 Cr142.92 Cr179.32 Cr189.32 Cr
Operating Expenses 146.00 Cr88.00 Cr-116.06 Cr127.94 Cr152.47 Cr161.79 Cr
Operating Income -4.00 Cr-2.00 Cr-22.30 L14.98 Cr26.85 Cr27.52 Cr
EBITDA 3.00 Cr4.00 Cr-10.83 Cr25.41 Cr52.24 Cr46.17 Cr
Interest Expense 3.00 Cr3.00 Cr-4.09 Cr4.96 Cr5.39 Cr1.37 Cr
Pretax Income -4.00 Cr-4.00 Cr--4.26 Cr8.52 Cr31.83 Cr28.93 Cr
Tax Provision -20.00 L-32.00 L-18.80 L-9.42 Cr6.45 Cr2.50 Cr
Net Income -5.00 Cr-5.00 Cr--3.97 Cr24.78 Cr31.77 Cr28.98 Cr
Diluted EPS -154.92-156.22--0.724.516.055.26

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 106.00 Cr106.00 Cr-96.54 Cr134.52 Cr284.67 Cr293.97 Cr
Current Assets ---53.16 Cr69.10 Cr187.06 Cr188.72 Cr
Cash & Equivalents ---95.80 L69.80 L90.82 Cr8.40 Cr
Inventory ---24.23 Cr24.72 Cr18.65 Cr21.75 Cr
Receivables ---20.42 Cr24.90 Cr36.68 Cr45.54 Cr
Total Liabilities ---77.06 Cr89.95 Cr75.96 Cr49.86 Cr
Current Liabilities ---57.27 Cr67.09 Cr56.70 Cr30.79 Cr
Long Term Debt ---11.30 Cr15.14 Cr10.61 Cr0
Total Debt 37.00 Cr39.00 Cr-38.71 Cr49.78 Cr19.51 Cr13.01 Cr
Total Equity 37.31 Cr33.31 Cr-17.79 Cr42.47 Cr208.54 Cr243.32 Cr
Shares Outstanding ---5.50 Cr5.50 Cr5.50 Cr5.50 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 12.00 Cr10.00 Cr-14.44 Cr8.15 Cr43.83 Cr-5.00 Cr
Investing Cash Flow -18.00 Cr-9.00 Cr--9.39 Cr-10.80 Cr-29.24 Cr-79.58 Cr
Financing Cash Flow 6.00 Cr-0--1.45 Cr-2.66 Cr110.64 Cr-17.75 Cr
Capital Expenditure -17.00 Cr-10.00 Cr--9.98 Cr-14.76 Cr-16.08 Cr-18.37 Cr
Free Cash Flow -5.00 Cr0-4.46 Cr-6.61 Cr27.75 Cr-23.37 Cr
Net Change in Cash 00-3.60 Cr-5.32 Cr125.23 Cr-102.33 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % ---73.2%74.7%75.8%69.7%
Operating Margin % -2.7%-2.2%-0.1%7.8%11.4%10.1%
Net Margin % -3.3%-5.4%--2.5%12.9%13.4%10.7%
ROE % -13.4%-15.0%--22.3%58.3%15.2%11.9%
ROCE % ---0.6%22.2%11.8%10.5%

Shareholding Pattern

Insiders
68.16%
Institutions
17.04%
Public Float
53.52%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for LAXMIDENTL

Google News hu, 25 Jun 2026

LAXMIDENTL Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE1hTzhFUkFnWjVzaUJ1ZDFDRDRSblBUTkZnLTZkZ3lINzAxbkdpWVY0YzV3RDBmbDFlQmZfaWJYX1JjQm84dDVhZ2FZWGF6aksxeFZDUnZFOHI4VDZGeWNNN3JMYzFsRzhzVkFaakEtRWhhT0E3ZGVSX1NJZUdQZw?oc=5" target="_blan…

Google News Fri, 29 May 2026

Laxmi Dental's (NSE:LAXMIDENTL) Weak Earnings May Only Reveal A Part Of The Whole Picture - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxPelpDV3RfZk5iS3oyanhESWJqUFNQMzYwZUhYWFhleWx3UlZEbllFMmVTSEVsLUkwUFZ4NHFFRUNGSWd6THNxLTNVMmFCbnFTZ2c1dGVCaC1SX2QxaEpkbmFlbnRhLXJFbVVzOEdnMU41bnNKWTFiQnp1Mm96T3hBTWMzSmI5WWR0WXhKS2…

Google News Wed, 01 Jul 2026

LAXMIDENTL Q2 2026 Earnings: Revenue Growth of 14.77% YoY Amid Market Headwinds - Earnings Call Q&A - vinanet.vn

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxOZEJfSDM1TTIwZktFMDJGVXV1MUU3NFNMNnBVbDRaM0lmXzJ3TWZyYkw2ZWprSmY0SUJWcGRHMnkxdWFfNEp4QUZpRTNidWg1aXQ3UjRzdHEzNG9WVGRsZ1hlT3BqYnRsV0s5SUNiQ01OU0N2QXYtcGdROXZIdUNRR19tVGRWcTBqNXUyYX…

Google News ue, 05 May 2026

LAXMI DENTAL LIMITED Share Price - Live NSE: LAXMIDENTL Stock Price & Chart - Upstox

<a href="https://news.google.com/rss/articles/CBMia0FVX3lxTE85WVR0YnVhbjYyN3lpRFNFOXg5TnlZN3B0QmlXRUZfTUUyVkVPS1p2azdDYzVzRV9oc2FJUnVwM0Q0bk1sVkp0WTZkeXptRmxxX3c5d052b0xZLTYxZmlhbXN1MVZmUEY4WlJz?oc=5" target="_blank">LAXMI DENTAL LIMITED Sh…

Google News Sun, 16 Nov 2025

Laxmi Dental Limited (NSE:LAXMIDENTL) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxOWTJXZzF2T0hLSEtnVGstSkFRQ3hpR2xOT1IxblY5WFVMclZfZlJvblBwVW5MVDZkWGRyRnJSaEtfRnRPdVhxN1pCUS1OeXplRHlLNlFZU3dyNnMwcERxVmZxRkI2SDdVYW1fdUo5U2Rmc09rdnoycHNPUU43M0NvZk1hVWZZN0NxdUxlQ1…

Google News Mon, 29 Jun 2026

Laxmi Dental Q2 2026 Earnings: Revenue Grows 14.8% YoY, EPS at ₹5.26 - Return On Equity - siam.in

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxOTDVPd21UMVJEN1EyNmJuamI0OExpRDJKYjdPZFlPc2NSUWlzNmh0akJEdnFHTkM5bTdpc0RjaDhRX1lJS3Zkb3h5ZEpra1hVZHhIbC1iOS1aX3B4bDlmUXdkRjFtTElvODBaSWNKNG5OdGNrMElocTdoaXppbUQ0SEcxUGo3ZmMzWXNyQ1…

LAXMIDENTL — Frequently Asked Questions

What is the current share price of LAXMI DENTAL LIMITED (LAXMIDENTL)?

As of 2026-09-08 04:53 IST, LAXMI DENTAL LIMITED (LAXMIDENTL) trades at ₹199.14 on NSE. Its 52-week range is ₹158.25 to ₹393.45.

What is the market capitalisation of LAXMIDENTL?

LAXMI DENTAL LIMITED (LAXMIDENTL) has a market capitalisation of ₹1,094.52 Cr on NSE.

What is the P/E ratio of LAXMIDENTL?

LAXMIDENTL trades at a trailing price-to-earnings (P/E) ratio of 37.86. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 4.89.

What is the return on equity (ROE) of LAXMIDENTL?

LAXMIDENTL has a return on equity (ROE) of 11.91%. Its return on capital employed (ROCE) is 11.51%.

Is LAXMIDENTL a good stock to buy?

This page provides a data-driven analysis of LAXMI DENTAL LIMITED (LAXMIDENTL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space